Articles tagged with Long Covid
Researchers have proposed a novel treatment strategy for post-acute infectious syndromes (PAIS), including Long COVID. The multimodal approach combines pharmacological interventions like metformin and low-dose naltrexone with physical therapies like extracorporeal apheresis.
Researchers discovered faulty immune processes responsible for lingering lung issues after COVID-19, which can be disrupted by existing drugs. The study also identified molecules responsible for the issue and potential therapeutic options for patients with ongoing lung damage.
A study published in Nature found that immune cells called CD8+ T cells prevent lung healing and repair post-infection, leading to pulmonary fibrosis. This discovery may lead to new therapeutic treatment options for patients with long COVID.
A new study from the University of Kansas reveals that individuals with pre-existing disabilities are more than twice as likely to develop long COVID. The research found that chronic illnesses and mental illness/psychiatric disabilities were the most common types of disabilities among those experiencing long COVID.
A new study published in JRSM Open found that pain is the most prevalent and severe symptom reported by individuals with long Covid, affecting 26.5% of participants. Demographic factors such as age, gender, ethnicity, education level, and socioeconomic status significantly impact symptom severity.
Researchers discovered that the blood coagulation protein fibrin causes unusual clotting and inflammation in COVID-19, suppressing the body's ability to clear the virus. A promising therapeutic strategy has been identified, targeting fibrin to combat these deleterious effects.